Meeting
2024 ASCO Annual Meeting
SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC).
Authors
David Bing Zhen
University of Washington/Fred Hutchinson Cancer Center, Seattle, WA
David Bing Zhen , Anna Moseley , E. Gabriela Chiorean , Earle F Burgess , Elizabeth M. Swisher , Carl Michael Gay , Lauren Averett Byers , Ignacio Ivan Wistuba , Haider Mahdi , Jason S. Starr , Megan Othus , Young Kwang Chae , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT05058651
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS4201)
DOI
10.1200/JCO.2024.42.16_suppl.TPS4201
Abstract #
TPS4201
Poster Bd #
170b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).
First Author: David Bing Zhen
First Author: Ana Oaknin
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2017 ASCO Annual Meeting
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
First Author: Howard Jack West